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We investigated the role of peripheral NMDA receptors (NMDARs) in antidromic nerve stimulation-induced tactile hypersensi-
tivity outside the skin area innervated by stimulated nerve. Tetanic electrical stimulation (ES) of the decentralized L5 spinal nerve,
which induced enlargement of plasma extravasation, resulted in tactile hypersensitivity in the L4 plantar dermatome of the hind-
paw. When intraplantar (i.pl.) injection was administered into the L4 dermatome before ES, NMDAR and group-I metabotropic
Glu receptor (mGluR) antagonists and group-II mGluR agonist but not AMPA/kainate receptor antagonist prevented ES-induced
hypersensitivity. I.pl. injection of PKA or PKC inhibitors also prevented ES-induced hypersensitivity. When the same injections
were administered after establishment of ES-induced hypersensitivity, hypersensitivity was partially reduced byNMDARantagonist
only. In na¨ıve animals, i.pl. Glu injection into the L4 dermatome induced tactile hypersensitivity, which was blocked by NMDAR
antagonist and PKA and PKC inhibitors. These results suggest that the peripheral release of Glu, induced by antidromic nerve
stimulation, leads to the expansion of tactile hypersensitive skin probably via nociceptor sensitization spread due to the diffusion
of Glu into the skin near the release site. In addition, intracellular PKA- and PKC-dependent mechanisms mediated mainly by
NMDAR activation are involved in Glu-induced nociceptor sensitization and subsequent hypersensitivity.
1. Introduction
Primary afferent nociceptors are responsible for converting
harmful stimuli in the peripheral tissue into internal electrical
impulses and then conveying these impulses to the central
nervous system for pain perception. In addition to their
afferent functions, evidence indicates that nociceptors also
have local efferent functions. Upon activation, nociceptive
afferents, especially the unmyelinated C-fibers that constitute
the largest proportion of cutaneous nociceptive afferents, are
able to provoke the local release of various algesic substances
at the peripheral terminals [1–3]. Indeed, stimulation of
C-fibers results in a local increase in levels of glutamate
(Glu), substance P (SP), and calcitonin gene-related peptide
(CGRP) [4–7]. Peripherally released algesic substances are
known to cause neurogenic inflammation [1, 8] and are also
likely to diffuse to receptors expressed on nearby nociceptors
in a paracrine manner to modulate neuronal excitability.
There is significant evidence for the modulatory role
of Glu in peripheral nociception. Both ionotropic and
metabotropic Glu receptors (mGluRs) are present in the
peripheral terminals of unmyelinated afferents [9–13]. The
subcutaneous injection ofGlu and specificGluR agonists pro-
duces pain behaviors that are blocked by their corresponding
antagonists [10, 14]. Furthermore, local injection of GluR
antagonists attenuates pain behaviors in various experimental
models of pain [9, 15–24]. In addition, peripheral Glu is able
to increase the excitability of nociceptors under both normal
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and pathological conditions [21, 25]. Glu-induced tactile
hyperalgesia is mediated by intracellular signaling pathways
that activate protein kinases such as protein kinases A (PKA)
and C (PKC) in the primary sensory neurons [26, 27].
In a previous study using rats with an injury to the
lumbar L5 spinal nerve (L5 SN) that had previously under-
gone a L5 dorsal root rhizotomy (DR) (decentralized L5
SN), we proposed Wallerian degeneration and peripherally
propagating injury discharge induced by nerve ligation/cut
as peripheral contributions to nerve injury-induced neuro-
pathic pain [28]. The present study was performed using the
same rhizotomized rats to investigate the role of peripherally
propagating nerve impulses, which were evoked by a tetanic
electrical stimulation (ES) that was revealed to release Glu
from peripheral terminals of primary afferent fibers [4],
in the development of hypersensitivity outside the skin
area innervated by the stimulated nerve. To achieve this
goal, we examined whether antidromic stimulation of the
decentralized L5 SN induces tactile hypersensitivity on the L4
plantar dermatome of the hind-paw. In addition, we explored
which subtypes of GluRs mediate such hypersensitivity. We
also examined whether PKA and PKC were involved in this
hypersensitivity.
2. Materials and Methods
2.1. Experimental Animals and Surgical Procedures. Adult
male rats (150–250 g; Harlan Sprague-Dawley, Koatech Co.,
Gyeonggi-do, Korea) were used. The animals were housed
in groups of three to four with food and water available
ad libitum. All animals were acclimated to a 12-12 light-
dark cycle for approximately 1 week before the surgery and
behavioral testing. All the experiments were conducted in
accordance with the approval of the Institutional Animal
Care and Use Committee of Yonsei University, Seoul, Korea.
All the surgical procedures were conducted under enflu-
rane anesthesia (2-3% enflurane-O
2
mixture). The animals
were initially subjected to an L5 DR before receiving sub-
sequent manipulations. For the L5 DR, a longitudinal skin
incision was made to expose the L3–L6 vertebral segments,
and a hemilaminectomy was performed at the left L5 seg-
ments. Care was taken to avoid any mechanical trauma to
the spinal cord, the dorsal roots, and the dorsal root ganglion
(DRG). The dura mater was opened, and the left L5 dorsal
root was exposed and sectioned 2-3mm proximal to the L5
DRG. A small portion of the distal end of the dissected root
was sectioned for removal.
2.2. Electrical Stimulation. A tetanic ES of the L5 SN was
conducted in rats that received a left L5 DR (Figure 1(a)).
In these rats, if mild tactile hyperalgesia had been present,
then it had worn off within a week after the rhizotomy. The
animals were under enflurane anesthesia throughout the ES
experiment. After removing the left transverse process of the
L6 vertebra, the left L5 SN was exposed. A piece of parafilm
was placed underneath the exposed SN to isolate it from
the surrounding tissue. A pair of thin flexible silver wires
(0.005 in diameter) was placed 4–6mm distal to the L5 DRG
to gently loop around the L5 SN (3mm apart).The other ends
of the wires were connected to a stimulus isolation unit (SI-
1850, World Precision Instruments, New Haven, CT, USA).
Square-wave pulses (0.5ms, 4Hz) were applied with graded
levels of current to determine the lowest level of current
needed to elicit a muscle twitch or the threshold current. The
current pulses at strengths 200 times the threshold current
(2–4mA, 200 × TH) were delivered for 5min to activate both
the A- and C-fibers in the L5 SN. For the sham-operated
group, all procedures were conducted in exactly the sameway
as for the ES-treated animals, except that no ESwas delivered.
The plasma extravasation, which is one of the character-
istic symptoms of neurogenic inflammation, was induced by
the ES of the L5 SN using extra animals that received an
intravenous injection of Evans blue dye (Sigma, St. Louis,
MO, USA) in the lateral tail vein (30mg/kg, 2% solution)
before the ES. The images of dye extravasation seen as blue
on the plantar surface were captured with a digital video
camera to determine whether changes in the extravasation
area occurred during the ES.
2.3. Drug Preparation and Administration. Noncompetitive
NMDA (N-methyl-d-aspartate) receptor (NMDAR) antag-
onist MK-801 and competitive AMPA (amino-3-hydroxy-5-
methylisoxazole-4-propionic acid)/kainate receptor antago-
nist NBQX (2,3-dioxo-6-nitro-1,2,3,4,-tetrahydrobenzo[f]quin-
oxaline-7-sulfonamide) were dissolved in phosphate-buff-
ered saline (PBS), pH 7.4. A competitive group-I mGluR
antagonist DL-AP3 (DL-amino-3-phosphonopropionic acid)
and selective group-II mGluR agonist APDC ((2R,4R)-4-
aminopyrrolidine-2,4-dicarboxylate) were first prepared as
a stock solution in 100mM NaOH and then diluted to
final concentrations with PBS. For PKA and PKC inhibi-
tion, staurosporine (a broad-spectrum kinase inhibitor) and
calphostin C (a selective PKC inhibitor) were first prepared
as a stock solution in 1mM DMSO and then diluted to the
final concentration with PBS. The Glu and H-89 (a selective
PKA inhibitor) were dissolved in PBS. All the drugs were
purchased from Tocris Cookson (Bristol, UK). Correspond-
ing vehicles were prepared in an identical manner without
the addition of the drug. The selection of drug doses used
in this study was based on our previous study in which the
effective doses of drugswithout obvious side effects have been
chosen [15].These drug concentrations were lower than those
used by other groups for various experiments, excluding the
possibility of off-target effects [16–18, 30, 31].
Under enflurane anesthesia (3%, 2-3min), 30 𝜇L of the
drugs or corresponding vehicles was injected subcutaneously
under the hind-paw skin using a 50 𝜇L Hamilton syringe
(Reno,NV,USA)with a 28-gauge needle. For this intraplantar
(i.pl.) injection, the needle was inserted into the skin in
the middle of the plantar surface proximal to the proximal
tori of the hind-paw and advanced approximately 10mm so
that it reached the center of the circle surrounded by the
tori, where the solution was injected and formed a bleb that
disappeared within 10min (Figure 1(b)). Pretreatments were
performed immediately (i.e., within 10min) prior to the ES,
and posttreatments were performed 3 days after the ES. To
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Figure 1: The locations of electrical stimulation (ES), intraplantar (i.pl.) injection of substances, and paw sensitivity testing and an example
of ES-induced plasma extravasation. (a) An L5 spinal nerve (SN) was decentralized by L5 dorsal rhizotomy (DR). A high-level tetanic ES
(2–4mA, 0.5ms pulse, 4Hz, and 5min) was applied to the decentralized L5 SN 4–6mm distal to the L5 dorsal root ganglion (DRG). (b)
The tactile sensitivity testing was performed in an area (marked by a filled circle) located in the center of the circle surrounded by the tori,
which is almost matched to the midpoint of the L4 plantar dermatome (shaded area) [29] of the hind-paw. A 30𝜇L i.pl. injection of different
substances was administered subcutaneously into the skin area subjected to tactile sensitivity testing, forming a bleb that disappeared within
10min after the injection (bleb area marked by a dotted circle). (c) Following Evans blue injection (i.v., 30mg/kg, and 2% solution), areas of
plasma extravasation induced by the ES of the L5 SN are seen as blue. Note that dye extravasation covered the L5 plantar dermatome within
the first 90 seconds of the ES, and the extravasation area extended to the L4 plantar dermatome within 4 minutes of the ES.
assess the antinociceptive effects of PKA and PKC inhibitors
on Glu-induced hypersensitivity in na¨ıve rats, pretreatment
was conducted 10min before theGlu treatment with both i.pl.
injections administered at the same site.
2.4. Behavioral Testing. Each rat was placed in a plexiglass
cage (8 × 8 × 20 cm3) above a wire mesh bottom that allowed
full access to their paws. Following a 15min acclimation
period, the rats underwent behavioral testing. Tactile hyper-
sensitivity was evaluated by measuring the paw withdrawal
threshold (PWT) upon the application of a von Frey filament
using the Dixon’s up-down testing paradigm [32]. A series of
von Frey filaments, ranging from 0.3 to 15.0 g, were applied
perpendicular to the center of the circle surrounded by the
tori of the hind-paw (avoiding the keratinized foot pads,
see Figure 1(b)) for 2-3 s until each filament bent slightly,
starting with a 2.5 g stimulus. For the PWT measurement,
the 50% withdrawal threshold was determined based on an
equation and the calibration table described by Chaplan et al.
[33]. Behavioral testing was performed by investigators who
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were blind to the surgery and treatment that the animals had
received.
2.5. Statistical Analysis. To determine the differences
between the different treatment groups on a given testing
day, the data were analyzed using a Mann-Whitney rank-
sum test or a Kruskal-Wallis analysis of variance (ANOVA)
followed by Dunn’s test for multiple comparisons. The
differences from baseline within a given treatment group
were analyzed using a Friedman repeated measures ANOVA
followed by Dunn’s test for multiple comparisons. 𝑃 < 0.05
was considered to be statistically significant. Data are
represented as mean ± SEM.
3. Results
3.1. Tetanic ES-Induced Tactile Hypersensitivity. We investi-
gated using rats with L5 DR whether a high-level tetanic
ES (2–4mA, 0.5ms pulse, 4Hz, and 5min) of the L5
SN (L5 SN-ES) induced tactile hypersensitivity on the L4
dermatome. The tactile sensitivity was tested by measuring
PWT using von Frey filaments applied to the center of the
hind-paw glabrous skin surrounded by the tori, which is
almostmatched to themidpoint of the L4 plantar dermatome
(Figure 1).This L5 SN-ES was observed to induce neurogenic
inflammation consistently in all test animals, as judged
by extravasated Evans blue, which covered the L5 plantar
dermatomewithin the first 90 seconds of the ES and extended
to the L4 plantar dermatome within 4 minutes of the ES. No
further enlargement of the extravasation zone was observed
during the remaining ES period. A typical example of ES-
induced plasma extravasation observed in five rats tested was
illustrated in Figure 1(c).
As for PWT changes (Figure 2), L5 SN-ES resulted in a
significant decrease in the PWTs of the L4 plantar dermatome
of the hind-paw ipsilateral to the ES as compared with the
baseline. This decrease in the PWTs lasted for 7 days from
poststimulation days 1 through 7. Such decreases also were
significant in comparison with the PWTs of sham animals or
the contralateral hind-paw.
3.2. Effects of Pretreatment in the Periphery with MK-801,
NBQX, DL-AP3, or APDC on ES-Induced Tactile Hyper-
sensitivity. The involvement of NMDA and AMPA/kainate
receptors in the initiation of L5 SN-ES-induced tactile hyper-
sensitivity of the L4 plantar dermatome was examined using
rats with decentralized L5 SN. As seen in Figure 3(a), an
i.pl. MK-801 (20 nM) injection up to 10min prior to the ES
into the midpoint of the L4 plantar dermatome of the hind-
paw ipsilateral to the ES resulted in a significant increase in
ES-induced decreased PWTs compared with vehicle-treated
controls. These data indicate that NMDARs in the L4 plantar
dermatome contribute to the initiation of L5 SN-ES-induced
tactile hypersensitivity. Animals administered an i.pl. NBQX
(100 nM) injection prior to the ES exhibited no significant
difference in ES-induced decreased PWTs compared with
vehicle-treated controls (Figure 3(b)), which indicates that
AMPA/kainate receptors in the L4 plantar dermatome are
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Figure 2: Tactile hypersensitivity following tetanic ES of the
decentralized L5 SN. A tetanic ES of the L5 SN (L5 SN-ES) in
rats with L5 DR induced a significant decrease in PWTs in the
affected hind-paws on days 1 through 7 after ES compared with
the baseline, contralateral hind-paws, and sham-operated animals.
The abbreviations B and D denote the baseline before DR and
postoperative days after DR, respectively. The figures in parentheses
indicate the number of animals used. The error bars represent the
SEM. ∗𝑃 < 0.05 versus sham animals. #𝑃 < 0.05 versus baseline.
##
𝑃 < 0.05 versus contralateral hind-paws.
unlikely to contribute to the initiation of L5 SN-ES-induced
hypersensitivity.
The involvement of mGluRs in the initiation of L5
SN-ES-induced tactile hypersensitivity of the L4 plantar
dermatome was investigated. As seen in Figures 3(c) and
3(d), animals administered an i.pl. injection of a competitive
group-I mGluR antagonist DL-AP3 (70 nM) or a selective
group-II mGluR agonist APDC (20 nM) prior to the ES
into the midpoint of the L4 plantar dermatome resulted
in a significant increase in ES-induced decreased PWTs as
compared with vehicle-treated controls. These data indicate
that the activation of group-I mGluRs and the inhibition of
group-IImGluRs in the L4 plantar dermatome are implicated
in the initiation of L5 SN-ES-induced hypersensitivity.
3.3. Effects of Posttreatment in the Periphery with MK-801,
NBQX, DL-AP3, or APDC on ES-Induced Tactile Hyper-
sensitivity. The involvement of NMDA and AMPA/kainate
receptors in the maintenance of L5 SN-ES-induced tactile
hypersensitivity of the L4 plantar dermatome was examined
using rats with a decentralized L5 SN. As seen in Figure 4(a),
an i.pl. injection of MK-801 (20 nM) into the midpoint of
the L4 plantar dermatome on day 3 after ES resulted in a
significant increase in ES-induced decreased PWTs at 15,
30, and 45min posttreatment compared with vehicle-treated
controls, which indicates a contribution of NMDARs in
the L4 plantar dermatome to the maintenance of L5 SN-
ES-induced hypersensitivity. Animals administered an i.pl.
injection of NBQX (100 nM) into the midpoint of the L4
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Figure 3: Effects of MK-801, NBQX, DL-AP3, or APDC pretreatment in the periphery on ES-induced PWT reduction. (a) In rats with
L5 DR, an i.pl. injection of MK-801 (20 nM) administered immediately before the ES of L5 SN (L5 SN-ES) into the midpoint of the L4
plantar dermatome resulted in a significant increase in ES-induced decreased PWTs compared with vehicle-treated controls. (b) An i.pl.
NBQX (100 nM) injection administered immediately prior to the ES produced no significant difference in ES-induced decreased PWTs from
vehicle-treated controls. (c and d) Animals administered an i.pl. injection of DL-AP3 (70 nM) or APDC (20 nM) immediately prior to the
ES exhibited a significant increase in ES-induced decreased PWTs compared with vehicle-treated controls. The abbreviations B and D are
defined in Figure 2. The values in parentheses indicate the number of animals used. The error bars represent the SEM. ∗𝑃 < 0.05 versus
vehicle groups. #𝑃 < 0.05 versus baseline.
plantar dermatome on day 3 after ES exhibited no significant
changes in ES-induced decreased PWTs compared with
vehicle-treated controls (Figure 4(b)), which indicates no
participation of AMPA/kainate receptors in the L4 plantar
dermatome in maintaining L5 SN-ES-induced hypersensitiv-
ity.
The involvement of group-I and -II mGluRs in the main-
tenance of L5 SN-ES-induced tactile hypersensitivity was
tested. As seen in Figures 4(c) and 4(d), animals administered
an i.pl. injection of DL-AP3 (70 nM) or APDC (20 nM) into
the midpoint of the L4 plantar dermatome on day 3 after
ES exhibited no significant changes in ES-induced decreased
PWTs compared with vehicle-treated controls. These data
indicate that neither group-I mGluRs nor group-II mGluRs
in the L4 plantar dermatome contribute to the maintenance
of L5 SN-ES-induced hypersensitivity.
3.4. Effects of Pre- and Posttreatment in the Periphery with
Staurosporine, Calphostin C, or H-89 on ES-Induced Tactile
Hypersensitivity. The involvement of the intracellular signal-
ing molecules PKA and PKC in the initiation of L5 SN-ES-
induced tactile hypersensitivity was tested using rats with
decentralized L5 SN. As seen in Figures 5(a), 5(b), and 5(c),
an i.pl. injection of staurosporine (a broad-spectrum kinase
inhibitor, 70𝜇M), calphostin C (12 𝜇M), orH-89 (10 𝜇M) into
the midpoint of the L4 plantar dermatome up to 10min prior
to the ES resulted in a significant increase in ES-induced
decreased PWTs compared with vehicle-treated controls.
These data indicate that both PKA and PKC participate
in initiating L5 SN-ES-induced hypersensitivity in the L4
plantar dermatome.
When an i.pl. injection was administered on day 3
after ES into the midpoint of the L5 plantar dermatome,
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Figure 4: Effects of MK-801, NBQX, DL-AP3, or APDC posttreatment in the periphery on ES-induced PWT reduction. (a) In rats with L5
DR, an i.pl. injection ofMK-801 (20 nM) administered 3 days after the ES of L5 SN (L5 SN-ES) into themidpoint of the L4 plantar dermatome
resulted in a significant increase in ES-induced decreased PWTs at 15, 30, and 45min after treatment compared with vehicle-treated controls.
(b–d) No differences in ES-induced decreased PWTs were observed between animals treated with NBQX (100 nM), DL-AP3 (70 nM), or
APDC (20 nM) and vehicle-treated controls. The abbreviations B, D, E, and Pre denote the baseline before DR, postoperative days after DR,
postoperative days after ES, and baseline prior to i.pl. injection, respectively. The values in parentheses indicate the number of animals used.
The error bars represent the SEM. ∗𝑃 < 0.05 versus vehicle group. #𝑃 < 0.05 versus baseline.
animals treated with staurosporine (70 𝜇M), calphostin C
(12 𝜇M), or H-89 (10 𝜇M) exhibited no significant changes
in ES-induced decreased PWTs compared with vehicle-
treated controls (Figures 6(a), 6(b), and 6(c)). No effects were
observed at higher doses of each drug. Thus, neither PKA
nor PKC are implicated in maintaining L5 SN-ES-induced
hypersensitivity in the L4 plantar dermatome.
3.5. Effects of Pretreatment in the Periphery with MK-801,
Calphostin C, or H-89 onGlu-Induced Tactile Hypersensitivity.
The involvement of NMDAR, PKA, and PKC in initiation of
Glu-induced tactile hypersensitivity was investigated using
na¨ıve rats. As seen in Figure 7, an i.pl. injection of Glu into
the midpoint of the L4 plantar dermatome of the hind-paw
in na¨ıve rats resulted in a significant decrease in PWTs,
which lasted approximately 6 h compared with the baseline.
An i.pl. injection of MK-801 (20 nM), calphostin C (12 𝜇M),
or H-89 (10 𝜇M) into the same site 10min prior to i.pl.
Glu injection produced a significant increase in Glu-induced
decreased PWTs compared with vehicle-pretreated controls.
These data indicate thatGlu induces tactile hypersensitivity in
the L4 plantar dermatome, and this hypersensitivity is likely
mediated by activation of NMDARs through intracellular
PKA and PKC signaling pathways.
4. Discussion
4.1. Tactile Hypersensitivity Induced by the Antidromic ES of
the Decentralized L5 SN. The efferent function of nociceptors
can be achieved via the release of algesic substances from
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Figure 5: Effects of staurosporine, calphostin C, or H-89 pretreatment in the periphery on ES-induced PWT reduction. (a–c) In rats with L5
DR, an i.pl. injection of staurosporine (70 𝜇M), calphostin C (12𝜇M), or H-89 (10 𝜇M) administered immediately prior to the ES of L5 SN
(L5 SN-ES) into the midpoint of the L4 plantar dermatome resulted in a significant increase in ES-induced decreased PWTs compared with
vehicle-treated controls. The abbreviations B and D are defined in Figure 2. The values in parentheses indicate the number of animals used.
The error bars represent the SEM. ∗𝑃 < 0.05 versus vehicle group. #𝑃 < 0.05 versus baseline.
their peripheral terminals by noxious stimulation [2] and
also by the antidromic propagation of impulses, for exam-
ple, peripherally propagating injury discharge produced by
damage to the peripheral nerve [28] and impulses traveling
toward the periphery through the dorsal root reflex and
axon reflex [2, 34]. The algesic substances released in the
periphery via the activation of nociceptors are involved in
the production of inflammation, which leads to nociceptor
sensitization [1, 8]. Thus, it is possible that algesic substances
released from the peripheral terminals of nociceptors may
sensitize nearby nociceptors through a diffusion or reflex
action. However, there has been much controversy over
whether the sensitization of nociceptors spreads beyond the
area of skin innervated by the injured or stimulated nerve
[35–41].This controversy is due, in part, to the use of different
methods for nociceptor stimulation and different animal
species for performing the experiments. Thus, conclusions
have been drawn from conflicting and contradictory data.
The tetanic ES of decentralized L5 SN is a useful way
to examine the involvement of peripherally propagating
impulses and subsequently released algesic substances in
pain hypersensitivity without considering the involvement
of central sensitization by employing L5 DR-bearing rats, in
which the central access of nerve impulses evoked by the
ES of L5 SN is completely blocked. In the present study, the
finding that tactile hypersensitivity developed in the center
of the circle surrounded by the tori of the hind-paw (i.e., the
midpoint of the L4 plantar dermatome) following the ES of
the decentralized L5 SN indicates that skin hypersensitivity
can occur near but outside the area of skin innervated by
the stimulated L5 SN (Figures 1 and 2). Although neural
mechanism of tissue hypersensitivity beyond the area of
original injury, that is, secondary hyperalgesia, is generally
considered to result from the sensitization of spinal dorsal
horn neurons, a solid conclusion has not yet been drawn [42,
43]. The behavioral hypersensitivity observed in the present
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Figure 6: Effects of staurosporine, calphostin C, or H-89 posttreatment in the periphery on ES-induced PWT reduction. (a–c) In rats with
L5 DR, an i.pl. injection of staurosporine (70 𝜇M), calphostin C (12𝜇M), or H-89 (10 𝜇M) administered 3 days after the ES of L5 SN (L5 SN-
ES) into the midpoint of the L4 plantar dermatome resulted in no significant difference in ES-induced decreased PWTs from vehicle-treated
controls. No effects were observed with higher doses of each drug. The abbreviations B, D, E, and Pre are defined in Figure 4. The values in
parentheses indicate the number of animals used. The error bars represent the SEM.
study can be accounted for by the sensitization of nociceptors
in the L4 plantar dermatome rather than centralmechanisms.
The importance of nociceptors supplying the L4 dermatome
in retaining behavioral hypersensitivity seen in our model
rats has previously been revealed by the complete blockage of
such hypersensitivity after the elimination of C-nociceptors
in the L4 SN with local capsaicin treatment [28].
One might argue that a prior L5 DR can alter the prop-
erties of central neurons to affect the tactile sensitivity in the
L4 dermatome. The barrage of impulses elicited briefly at the
time of the dorsal root transection, degeneration of proximal
stump of transected dorsal root, and enlarged receptive fields
of dorsal horn neurons in the L5 spinal segment might be
involved. Indeed, a mild tactile hypersensitivity was induced
in the L4 dermatome by the L5 DR. Although the underlying
mechanisms involved are not clear, this mild hypersensitivity
following the L5 DR completely vanished in less than a
week and did not reappear thereafter throughout the 12-
week observation period [28], suggesting a return of response
properties of affected neurons to the normal state before the
ES experiment commenced. In the present study, observed
plasma extravasation by tetanic ES of the L5 SN was not
inducible by the L5 DR alone (data not shown), suggesting
no noticeable effects of a prior L5 DR on response properties
of nociceptors in the periphery. Thus, it is possible to
assume that the tactile hypersensitivity in the L4 dermatome
following the ES of the decentralized L5 SN and subsequent
pharmacological modulation would not be confounded by a
prior L5 DR.
4.2. Importance of NMDARs in Antidromic ES-Induced
Hypersensitivity. The importance of the peripheral Glu and
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Figure 7: Effects of MK-801, calphostin C, or H-89 pretreatment
in the periphery on Glu-induced PWT reduction. In naive rats, an
i.pl. injection of Glu (1 𝜇M) into the midpoint of the L4 plantar
dermatome resulted in a significant decrease in PWTs that lasted
approximately 6 h compared with the baseline. Animals adminis-
tered an i.pl. injection of MK-801 (20 nM), calphostin C (12 𝜇M),
or H-89 (10𝜇M) 10min prior to the i.pl. injection of Glu at the
same site exhibited a significant increase in Glu-induced decreased
PWTs compared with vehicle-pretreated controls. B denotes the
baseline before the i.pl. injections of the test substances. The values
in parentheses indicate the number of animals used. The error bars
represent the SEM. ∗𝑃 < 0.05 versus vehicle group. #𝑃 < 0.05 versus
baseline.
its receptors in developing tactile hyperalgesia has been
acknowledged. The peripheral inhibition or activation of
specific GluRs has been shown to attenuate enhanced tactile
sensitivity in various experimental animal models of pain,
for example, inflammatory [17, 19, 21, 22] and neuropathic
[15, 23] pain, which are believed to bemediated at least in part
by the increased sensitivity of nociceptors to tactile stimuli
[44, 45]. In the present study, the local blockade of NMDARs
or group-ImGluRs or the local activation of group-IImGluRs
in the L4 dermatome completely blocked the decentralized
L5-SN-ES-induced tactile hypersensitivity (Figure 3), and an
NMDAR antagonist administered locally into the L4 der-
matome reversed such already established hypersensitivity
(Figure 4).These findings suggest the expansion of the area of
mechanically hypersensitive skin to the L4dermatome,which
can be accounted for by the spread of nociceptor sensitization
through the diffusion of Glu into the L4 dermatome from the
release site in the L5 dermatome.
It is well known that NMDARs play a key role in
the central sensitization of spinal nociceptive neurons [46–
48]. In addition, the data in the present study indicate the
importance of peripheral NMDARs but not AMPA/kainate
receptors in the induction and maintenance of behavioral
hypersensitivity (Figures 3 and 4), in accordance with a
previous report in which the local inhibition of peripheral
NMDARs in humans prevented the development of sec-
ondary hyperalgesia by a peripheral action [43]. Our data
also revealed that the behavioral hypersensitivity could be
blocked by the activation of peripheral group-II mGluRs,
which suggests a desensitization of peripheral nociceptors
via the activation of group-II mGluRs. A previous study has
shown that group-I mGluRs are coexpressed with group-
II mGluRs in peripheral afferent neurons [49]. In addition,
the intrathecal administration of group-I mGluR agonists
produces hyperalgesia [50], and the activation of group-
I mGluRs results in the hyperexcitability of spinal dorsal
horn neurons [51]. Thus, the coactivation of group-I and -II
mGluRs by Glumay produce no changes in the excitability of
nociceptors and subsequent behavioral sensitivity. We have
previously shown that the local administration of group-
I mGluR antagonists and group-II mGluR agonists in the
periphery each hinders the initiation of tactile hypersensi-
tivity in our modified neuropathic pain model whereas a
nonselective antagonist of mGluR produces no such effect
on hyperalgesia [15]. Although the coactivation of group-I
and group-II mGluRs by Glu is less likely to participate in
nociceptor sensitization and behavioral hypersensitivity, the
use of substances that selectively block group-I mGluRs or
selectively activate group-II mGluRs together with those that
block NMDARs may prevent pain hypersensitivity related to
nociceptor sensitization in the periphery.
4.3. Involvement of PKA and PKC in Antidromic ES-Induced
Hypersensitivity. Some signal transduction receptors essen-
tial for sensing noxious mechanical stimuli have been identi-
fied in sensory neurons, which include the transient receptor
potential Vanilloid 1 and Ankyrin 1 (TRPV1 and TRPA1)
and piezo-type mechanosensitive cation channels (Piezo).
For example, TRPA1 which is sensitized through various
intracellular kinases such as PKA and phospholipase C
(PLC) by inflammatory mediators, including bradykinin and
prostaglandins, plays a critical role in tactile hyperalgesia [52–
55].
We demonstrated in the present study that antidromic
nerve stimulation-induced tactile hypersensitivity was
blocked by pretreatment with inhibitors of PKA and PKC in
the periphery (Figure 5), which indicates the involvement
of activated peripheral PKA and PKC in the initiation of
tactile hypersensitivity. The tactile hypersensitivity observed
in our study can be considered to be the result of the PKA-
and PKC-dependent sensitization of nociceptors to tactile
stimuli mediated by peripheral Glu. There are several ways
to account for such nociceptor sensitization. First, peripheral
Glu activates adjacent nociceptors to release neuropeptides
that attract and activate immune cells to release inflammatory
mediators, resulting in nociceptor sensitization through
protein kinase-dependent activation of transduction recep-
tors as described above. Indeed, there are numerous pieces
of evidence implying that SP and CGRP released from the
peripheral terminals of primary sensory neurons induce
nociceptor sensitization through the stimulation of immune
cells to release inflammatory mediators [56–61]. Piezo2
on sensory neurons also can be involved in mediating
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inflammatory mediator-induced nociceptor sensitization.
The potentiation of the activity of piezo2 through PKA
and PKC has been found to mediate bradykinin-induced
tactile hyperalgesia [62, 63]. Second, peripheral Glu, which
binds to NMDARs on the nearby nociceptors, can sensitize
these nociceptors through the intracellular protein kinase-
dependent activation of transduction receptors. It has been
shown that NMDA-induced tactile hyperalgesia is mediated
by the activation of TRPV1 through CaMKII and PKC
signaling cascades in trigeminal ganglion neurons [26, 27].
Third, the potentiation of NMDAR activity by mGluRs in
sensory neurons via intracellular signaling pathways can be
involved in NMDAR-mediated sensitization of nociceptors.
Several pieces of evidence support this possibility. The
activation of group-I mGluRs facilitates NMDAR-mediated
responses in spinal dorsal horn neurons in the inflammatory
hyperalgesic state [51]. The enhanced nociceptive processing
in amygdala neurons by the activation of group-I mGluRs
is mediated by reactive oxygen species (ROS) that activate
PKA and ERK [64, 65]. ROS are known to serve as important
intracellular signaling molecules in peripheral and central
pain mechanisms [66–69].
Our findings that tactile hypersensitivity induced by
antidromic stimulation of L5 SN or by i.pl. Glu injected
into the L4 dermatome was blocked by pretreatment with
an NMDAR antagonist and both PKA and PKC inhibitors
in the L4 dermatome (Figures 3, 5, and 7) strongly support
the idea that peripherally released Glu sensitizes nearby
nociceptors through PKA- and PKC-dependent mechanisms
mediated by NMDAR activation to induce pain hypersensi-
tivity. Although, in the present study, we have not attempted
to determine specific neuronal cell types involved in periph-
eral Glu- or ES-induced pain hypersensitivity and PKA/PKC
expression patterns, unmyelinated C-nociceptors are likely
critically involved in this pathway.Most of all, capsaicin sensi-
tive afferents are clearly required for ES-induced mechanical
hypersensitivity [28]. Also, the fact that candidate molecules
responsible for the Glu- or inflammation-induced mechan-
ical hypersensitivity via the PKA or PKC signaling pathway
(e.g., TRPV1 [26, 27], TRPA1 [54, 55], and TTX-resistant
sodium channels [70, 71]) are preferentially expressed on C-
nociceptors supports this notion. Nevertheless, further study
is warranted to confirm this possibility.
The already established tactile hypersensitivity follow-
ing antidromic nerve stimulation was partially reversed by
the blockade of NMDARs but not AMPA/kainate recep-
tors, group-I mGluR, PKA, or PKC (Figures 4 and 6),
which suggests that hypersensitivity is partly maintained
by NMDAR activation. These results raise the possibility
of the involvement of other NMDAR-mediated signaling
molecules, such as ROS, PLC, and ERK, various transduction
receptors, and other types of mGluRs in the maintenance of
this hypersensitivity.
5. Conclusions
Our data suggest that peripheral Glu released by the
antidromic stimulation of the decentralized SN results in
the expansion of the area of tactile hyperalgesia via the
spread of nociceptor sensitization, which is mediated by the
diffusion of Glu into the skin near the release site. Our
data also imply that intracellular PKA- and PKC-dependent
mechanisms mediated mainly by NMDAR activation are
involved in Glu-induced nociceptor sensitization and subse-
quent tactile hypersensitivity.
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